Argenx Buys Forte for $2.2B

DallasArgenx pays $2.2 billion for zero approved drugs.

Forte’s $77-a-share price, a 41% premium, buys a molecule and patent position, not revenue — biopharma now buys pipelines instead of building them.

Argenx’s existing rare-disease drug, Vyvgart, already prices its treatments at the market’s extreme.

Sources: STAT